IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Re gional Strat egy
• Takeda hopes to be in the US top 15
Takeda is a Jap a nese leader in es tab lish ing it self over seas and gen er ates a much higher pro por tion of its
sales in the US mar ket than most Jap a nese com pa nies. This is how ever be ing threat ened with forth com -
ing pat ent ex pi ra tions of lead ing prod ucts, and in fis cal 2007 (end ing March 2008) Takeda’s share of
com pany sales gen er ated in the US dropped from nearly one-third to one-quar ter. Takeda now claims it
will be one of 15 lead ing com pa nies in the US how ever, fol low ing the pur chase of Abbott’s share of TAP,
which has now merged with Takeda to be come a wholly owned sub sid iary of Takeda Amer ica Hold ings,
Inc, 100%-owned by Takeda. Takeda ex pects syn er gis tic ef fects of about Yen40 bil lion over the
three-year pe riod fol low ing the merger, which com pleted in te gra tion and started busi ness as a new con -
sol i dated com pany in July 2008. As sets were split equally. Abbott ob tained rights to Lupron De pot along
with as sets pri mar ily re lated to this prod uct, and all em ploy ees as well as pay ments based on TAP’s other
cur rent and cer tain fu ture prod ucts. The new TAP sub sid iary of TAH will re tain the other mar keted TAP
prod uct, Prevacid (al though Abbott will re ceive around $1.5 bil lion from prod uct sales over five years).
Around 2,600 of the 3,000 em ploy ees of TAP (in clud ing 1,400 MRs) were trans ferred to the Takeda
group; the num ber of MRs of the new Takeda group has in creased to about 3,500. TAP de vel op ment
func tions have been trans ferred to Takeda Global Re search and De vel op ment Cen tre (TGRD) by trans -
fer ring TAP pipe line prod ucts: Kapidex (dexlansoprazole/TAK 390MR), a pro ton pump in hib i tor ap proved
in Jan u ary 2009; an other pro ton pump inhibior, ilaprazole (IY 81149) and Uloric (febuxostat/TMX 67) for
the treat ment of hyperuricemia in pa tients with gout, ap proved in Feb ru ary 2009. Takeda Phar ma ceu ti -
cal North Amer ica (TPNA) will now have two new prod uct launches dur ing the first half of 2009. TPNA has
grown from hav ing 6 em ploy ees in 1998, when it was in cor po rated, to 3,000 in 2006. In many ways,
given the im por tance of the US market and the lack of growth opportunities elsewhere, the success of
TPNA could be seen as a symbol for the success of Takeda itself.
Takeda is cur rently pres ent in Ja pan, the US, six Eu ro pean coun tries and five Asian coun tries and in its
last man age ment plan, it set it self the goal of main tain ing its lead ing po si tion in Ja pan, with a mar ket
share of 7%. In the all-im por tant US mar ket, the com pany wants TPNA to achieve a mar ket share of
more than 1.5%, and in Eu rope it ex pects more than 1.1% mar ket share in the six larg est coun tries. In
the five main coun tries in Asia, Takeda has set a tar get of more than 1.4% mar ket share. The tar get over -
all mar ket share is 2.5% in the coun tries where Takeda has its own sales chan nels. Takeda has how ever
re cently ad mit ted to strug gling in its at tempts to strengthen its pres ence in Eu rope and fully entering
emerging markets.
Ther a peu tic Fo cus
• On col ogy ac qui si tion may bridge loom ing gap
Takeda is well po si tioned with re gard to ther a peu tic fo cus; for many years, a large pro por tion of sales
have been gen er ated from the high growth di a be tes and on col ogy ar eas, as well as anti-ulcerants; oral
antidiabetics; an gio ten sin II an tag o nists; and cephalosporin an ti bi ot ics. Its ma jor prod ucts are
Prevacid/Takepron (lansoprazole), a pro ton pump in hib i tor; Actos (pioglitazone), an oral agent for di a be -
tes; the can cer and hor monal prod uct Leuplin/Lupron (al though this is now ex clu sively owned by Abbott
fol low ing the dis so lu tion of the TAP jv); and the an gio ten sin II in hib i tor Blopress/Atacand (candesartan
cilexetil) for hy per ten sion. Takeda faces a huge chal lenge as all four prod ucts lose pat ent pro tec tion over
the next five years with Prevacid in No vem ber 2009 fol lowed by Actos in 2011 then Blopress in 2012 and
finally Leuplin in 2014.
Blopress was the best sell ing phar ma ceu ti cal prod uct in Ja pan in the year end ing Sep tem ber 2008 ac -
cord ing to IMS. Takeda is de vel op ing a fixed-dose com bi na tion of candesartan with the cal cium an tag o -
© 2009 IMS Health In cor po rated or its af fil i ates Page 10